KINETIC-TECHNOLOGIES
15.11.2022 07:01:41 CET | Business Wire | Press release
Power management and video/audio interface IC leader Kinetic Technologies announced two new milestone products that can increase the Power Delivery capability of USB Type-C ports to 140W, removing the barrier to expanding the range of electronic products charged via USB. The KTS1898 is dedicated to switching and protecting VBUS power, while the KTU1128 is dedicated to switching and protecting the CC1/2 and SBU1/2 lines.
The KTS1898 is a low-resistance, 5A load switch with soft-start, overvoltage, “ideal diode” reverse-current, short-circuit, over-current, over-temperature and ESD protection plus integrated surge protection of ±100V, designed to isolate and protect downstream components from abnormal VBUS voltage and current conditions. The fast reverse current protection (ideal diode) allows multiple power paths to be connected to VBUS OUT without interference.
The KTU1128 companion IC is a Thunderbolt compatible, Type-C USB data line protection and switch IC, providing low-resistance, ultra-fast OVP, and surge protection for the CC and SBU lines. Maintaining pin-to-pin compatibility with existing products, the KTU1128 increases the operating tolerance on CC and SBU lines to 32V for short-to-VBUS protection and reduces the quiescent current.
“The KTS1898 and KTU1128 are industry leading devices that allow designers to implement USB Type-C PD3.1 Extended Power Range (EPR) up to 140W and effectively address safety at the same time,” says Erik Ogren, Kinetic Technologies Senior Director of Marketing. “With the ability to withstand up to +35V on VBUS, the KTS1898 delivers the margin our customers require to build 28V systems that are designed to be safe and reliable, while the super low-resistance 25mΩ MOSFET keeps heat to a minimum, which is essential when operating at such high-power levels. The KTU1128 features the same built-in robust protection and together extends Kinetic’s lead in this application.”
KTS1898 and KTU1128 samples are available now with production starting in first quarter 2023. Visit Kinetic Technologies for further information.
Key Product Highlights:
KTS1898 – 28V VBUS Protection
-
3V to 32V Operating Voltage Range
- 35V Abs Max. Rating at IN & OUT
-
5A Continuous Current Rating
- 10A peak
- Supports 140W USB Power Delivery 3.1 (EPR)
- “Ideal Diode” Reverse-current protection with 15µs fast recovery
- Full Protection: OVP, SCP, OCP, OTP & RCP
- IEC61000-4-5 Surge Protection ±100V
- IEC61000-4-2 ESD Protection ±15kV Air, ±8kV Contact
KTU1128 – 28V CC/SBU Protection
-
2.5V to 5.5V Operating Voltage Range
- 32V DC Tolerance on CC1/2, SBU1/2
- Thunderbolt Compatible
- Fast 70ns OVP response time
- IEC61000-4-5 Surge Protection ±40V/±30V CC/SBU
- IEC61000-4-2 ESD Protection ±15kV Air, ±8kV Contact
About Kinetic Technologies
Kinetic Technologies is a global designer, developer, and provider of proprietary and innovative high-performance analog and mixed-signal semiconductor products for a wide variety of markets. Kinetic’s products help its customers efficiently regulate power, intelligently protect their devices from harmful voltage and current spikes, and deliver high-bandwidth, low-latency, and secured connectivity for video, display, and general-purpose applications.
For more information, please visit http://www.kinet-ic.com/.
*Kinetic Technologies’ logo is a trademark of Kinetic Technologies. All other brand and product names appearing in this document are the property of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221113005095/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom